Accrol Group Holdings Analyst Q&A “strong ongoing growth” (LON:ACRL)

Accrol Group Holdings plc (LON:ACRL) is the topic of conversation when Zeus Capital’s Head of Research Mike Allen caught up with DirectorsTalk for an exclusive interview.

Q1: Accrol Group Holdings earlier this month announced the acquisition of LTC. This looks like a good deal for the company, what are your thoughts on that position?

A1: We think it’s a very good deal, a very good fit between the two businesses as well so LTC is a very established, it’s well-invested tissue converter and if you look at the financial track record it’s delivered, we think that kind of speaks for itself.

So, we’ve seen a compound average growth rate between 2017 and 2019 of about 70%, it brings for high quality tissue conversion lines as well and we think that it’ll take the combined revenue capacity to around £220 million on very new kit as well.

Also, I think it takes the group’s private label market share from about 26% above 30% so considering what we think they paid for it in terms of less than five times EBITDA, when you incorporate some of the anticipated cost synergies then we think that’s an attractive price for a strategically important business.

Q2: So, presumably you’ve upgraded your forecasts?

A2: Yes, so I think in the first full year of ownership, to April 20 22, we think this will be about 14% EPS-enhancing on what we believe to be conservative assumptions. We think that accretion could grow if there were more contracts and also new synergies come through as well, which we’ve not factored into this transaction.

So, it stacks pretty well financially.

Q3: Just picking out those synergies, what are the key benefits of this deal?

A3: So, obviously, there’s new customers that they can integrate, the business has got some new equipment and that gives it more capacity, the business in itself is high growth with good margins as well. There’s clearly room for cost synergies and revenue synergies in this business.

I think given the track record of the management team the growth market Accrol Group Holdings finds itself in with the discounts of having that extra capacity, with a strong management team, should lead to a strong ongoing growth over the next couple of years.

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Accrol Group Holdings plc

More articles like this

Accrol Group

Greenarc partnered with Accrol to install onsite EV chargers

Accrol Group Holdings plc (LON:ACRL) is the UK’s leading independent tissue converter, producing toilet tissue, kitchen towel, facial tissue and biodegradable wet wipes. The UK soft tissue market is worth £1.6bn with private label products comprising

Accrol Group

UK manufacturing industry sees £48.5bn productivity boost in 2023

The UK manufacturing industry achieved productivity improvements worth £48.5bn in 2023, according to analysis of ONS data by Fourjaw Manufacturing Analytics, a technology company that measures machine productivity. This represents an 8.6% increase on 2022 levels

Accrol Group

Accrol Group returns to profit

Accrol Group, the Blackburn-based AIM-listed tissue and toilet roll maker, has achieved a return to profit, despite a dip in revenues, for its interim period of trading. In the six months to October 31, 2023, the

Accrol Group

Manufacturers say UK becoming more competitive as global hub

Despite challenges such as high energy costs and political instability, Britain’s largest manufacturers see the UK as a growing global manufacturing hub. A recent survey revealed increased confidence in the sector’s prospects. Accrol Group Holdings plc is a leading UK tissue converter, contributing to the £1.6bn soft tissue market.

Accrol Group

Manufacturing outlook for 2024

Britain’s manufacturers have seen output surge by three times faster than orders in the last quarter, to +10% from a negative balance in Q3 of -3%. Such an increase is an extremely rare occurrence and potentially